Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the alcoholic beverages business, gross profit increased by ¥110 million due to higher revenue and by ¥250 million due to higher selling prices. These gains were offset by a ¥380 million increase in cost of sales due to higher raw material costs, a ¥150 million increase in selling, general and administrative expenses, including personnel expenses, and an ¥38 million impact from product mix and other factors. The enzyme pharmaceuticals business posted higher profit due to increases in exported enzymes and contract fermentation services.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥43,673 million (YoY +3.3%) |
| Operating profit | ¥2,557 million (YoY +10.4%) |
| Ordinary income | ¥2,650 million (YoY +10.5%) |
| Profit attributable to owners of the parent | ¥1,970 million (YoY +6.2%) |
| Net income per share | ¥35.06 |
| Equity ratio | End of the current fiscal period 49.2 / End of previous period 44.2 |
| Total assets | ¥55,815 million |
| Net assets | ¥28,240 million |
| Cash flows from operating activities | ¥35 million |
| Cash flows from investing activities | ¥-1,109 million |
| Cash flows from financing activities | ¥1,021 million |
| Cash and cash equivalents at end of period | ¥826 million |
| Full-year earnings forecast | Net Sales ¥89,000 million (YoY +1.6%) / Operating profit ¥3,950 million (YoY -4.5%) / Ordinary income ¥4,000 million (YoY -6.8%) / Net income ¥2,900 million (YoY -6.5%) |
| Segment revenue | Alcoholic beverages ¥39,997 million (YoY +2.4%), Enzyme pharmaceuticals ¥2,966 million (YoY +17.8%), Real Estate ¥665 million (YoY +0.7%) |
| Segment profit | Alcoholic beverages ¥1,219 million (YoY -9.8%), Enzyme pharmaceuticals ¥936 million (YoY +64.6%), Real Estate ¥396 million (YoY +1.7%) |
| Depreciation and amortization | ¥1,024 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥69 million, Gain on sale of investment securities ¥19 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥31 million, Other ¥2 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Availability of Supplementary Financial Results Materials | Yes |
| Factors Behind Changes in Business Performance | In the alcoholic beverages business, gross profit increased by ¥110 million due to higher revenue and by ¥250 million due to higher selling prices. These gains were offset by a ¥380 million increase in cost of sales due to higher raw material costs, a ¥150 million increase in selling, general and administrative expenses, including personnel expenses, and an ¥38 million impact from product mix and other factors. The enzyme pharmaceuticals business posted higher profit due to increases in exported enzymes and contract fermentation services. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Overseas sales were strong in the enzyme pharmaceuticals business, while higher selling prices and strong performance by certain products contributed to the alcoholic beverages business. On the other hand, increases in raw material costs, personnel expenses and other costs in the alcoholic beverages business weighed on profit.